BUZZ-Kineta rises on resuming enrollment in early-stage cancer study

Reuters08-19

** Shares of drug developer Kineta rise 13.5% to 64 cents

** Co says it has resumed enrollment, effective immediately, for its ongoing early-stage trial testing its experimental cancer treatment- KVA12123

** Co previously said enrollment was suspended "due to certain investors indicating that they would not fulfill their funding obligation due in April 2024"

** Co says 30 patients have been enrolled in the trial to date, including a monotherapy arm with just KVA12123 and a combination arm testing KVA12123 together with Merck's Keytruda

** Anticipates the trial to be fully enrolled by the end of 2024- KA

** Co says initial results of KVA12123 showed a favorable clinical safety and tolerability profile

** Including session moves, stock down 82.1% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment